通心络对急性冠脉综合征患者的疗效及安全性研究  

Efficacy and safety of Tongxinluo capsule in patients with acute coronary syndrome

作　　者：石海莉[1] 王子超[2] 孙漾丽[1] 

机构地区：[1]郑州市中心医院心内科,河南郑州450007 [2]郑州大学研究生院

出　　处：《心血管康复医学杂志》2005年第5期464-466,共3页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探讨通心络对急性冠脉综合征(ACS)治疗的有效性、安全性和预防心脑血管事件的益处。方法:77例ACS患者被随机分为两组:治疗组39例(ACS常规治疗+通心络胶囊);对照组38例(ACS常规治疗)。随访1年。结果:通心络组较对照组显著改善心绞痛(总有效率分别为89.7%与68.4%),改善心电图心肌缺血(总有效率分别为58.9%与39.5%);通心络组降低凝血酶活性、纤维蛋白原浓度的作用均明显优于对照组(P<0.05);通心络组治疗半年,明显改善左室射血分数(LVEF),左室短轴缩短率(FS),二尖瓣快速充盈期和心房收缩期血流速度比(E/ A)且明显优于对照组(P<0.05)。通心络组随访1年中复发性心绞痛、心力衰竭、需PTCA/CABG者均较对照组明显降低(P<0.05),且不良反应少。结论:急性冠脉综合征应用通心络安全有效,可预防心脑血管事件发生。Objective： To observe the efficacy and safety of Tongxinluo capsule in patients with acute coronary syndrome （ACS）. Methods：The 77 ACS patients were randomly divided into Tongxinluo group （n= 39）and control group （n=38） . In Tongxinluo group patients received routine anti-ACS treatment and Tongxinluo; the patients in control group were only treated by routine anti-ACS treatment ; the followed time was i year. Results ： For release ACS symptom, the efficiency of Tongxinluo group and control group was 89.7 % and 68. 4 % respectively（P〈0. 05） ;for improve ischemic ST-T changes in ECG, the efficiency of Tongxinluo group and control group was 58.9% and 39.5% respectively （P〈0. 05）. The active of thrombin and fibrinogen level decreased （P〈0. 05）, the LVEF,left ventricula shortening fraction （FS） and E/A ratio after 6 months increased （P〈0.05） in Tongxinluo group compared with control group. The anginarec, heart failure and PTCA/CABG of Tongxinluo group were less than those of control group （P〈0. 05） . The side effect of Tongxinluo group was few. Conclusion： On the basis of routine anti-ACS treatment to take Tongxinluo capsule is an efficacy and salt treatment, may prevent cardio-brain vascular events.

关 键 词：冠状动脉疾病 通心络胶囊 治疗结果 安全 

分 类 号：R541.409[医药卫生—心血管疾病]